

**/ immatics biotechnologies strengthens Supervisory Board with Dr. Klaus Stöckemann /**

(Tübingen, November 22, 2005) – Tübingen-based immatics biotechnologies GmbH, a leading company in the development of peptide-based therapeutics for cancer immunotherapy, has won 3i Partner Dr. Klaus Stöckemann as another top-class member for its Supervisory Board. Dr. Stöckemann, who holds a doctorate in  
5 Biology and Pharmacology as well as a MBA, will be replacing Prof. Erich Schlick, who will remain involved in the company as a consultant. In addition to Dr. Stöckemann, the immatics Supervisory Board now consists of Actelion co-founder Dr. Thomas Widmann, the CSO of GPC Biotech Dr. Sebastian Meier-Ewert, Dr. Ulrich Granzer, Wellington General Partner Dr. Rainer Strohmenger, and Prof. Dr.  
10 Hans-Georg Rammensee, Director of the Institute of Immunology at the University of Tübingen.

Klaus Stöckemann has more than 12 years' experience in the pharmaceutical industry. He was formerly Director of Research and a Senior Manager in Business  
15 Development at Schering AG in Berlin before becoming Director of Business Development at ASTA Medica, a Degussa & Huels group company in Frankfurt. In his capacity as Partner, he is in charge of the German-speaking region for the 3i Healthcare Venture Capital Team. At 3i, he was responsible for the Epigenomics AG IPO in 2004, and the Jerini AG IPO in November 2005.

20

In addition to his seat on the immatics board, Klaus Stöckemann is also a member of the Supervisory Board at Jerini AG, Combinature Biopharm AG, and Elbion AG.

"We are excited about the addition of Dr. Stöckemann, an acknowledged  
25 pharmaceutical expert, to our Supervisory Board. immatics can profit enormously from his business development and capital market expertise," notes Dr. Thomas Widmann, Chairman of the immatics Supervisory Board.

### **About immatics**

immatics (www.immatics.com) is an independent biopharmaceutical company that is  
30 dedicated to the development of new therapeutic substances for cancer  
immunotherapy. immatics' product candidates are based on tumour-associated  
peptides (TUMAPs), which stimulate the immune system specifically to fight cancer  
cells. The company will launch an international clinical study on the treatment of renal  
cell carcinoma (RCC) with its first product candidate IMA901 in the 4th quarter of 2005 –  
35 less than two years after concluding its first round of funding totalling EUR 14 million.  
Additional product candidates, which are also peptide-based immunotherapeutics, are  
currently in preclinical development and are the basis for a rapidly growing pipeline of  
products.

40 Published by: immatics biotechnologies GmbH: Dr. Niels Emmerich, Paul-Ehrlich-Straße 15,  
D-72076 Tuebingen, Germany, +49 (0)7071-565125-0, [emmerich@immatics.com](mailto:emmerich@immatics.com)